The acute or chronic drug treatments for different neurodegenerative and psychiatric
disorders are challenging from several aspects. The low bioavailability and limited brain …

Treatment of neurodegenerative diseases or other central nervous system (CNS) disorders
has always been a significant challenge. The nature of the blood-brain barrier (BBB) limits …

Central nervous system (CNS) disorders (eg, multiple sclerosis, Alzheimer's disease, etc.)
represent a growing public health issue, primarily due to the increased life expectancy and …

Neurological diseases continue to increase in prevalence worldwide. Combined with the
lack of modifiable risk factors or strongly efficacious therapies, these disorders pose a …

Introduction: The blood–brain barrier (BBB) represents a stringent barrier for delivery of
neurotherapeutics in vivo. An attempt to overcome this barrier is represented by the direct …

Background Controlled release and targeted delivery of the drug payload are the two most
fascinating applications of nanoparticle-based systems explored in the recent past. The …

The global prevalence of neurologic disorders is rising, and yet we are still unable to deliver
most drug molecules, in therapeutic quantities, to the brain. The blood brain barrier consists …

Background: The management of various central nervous system (CNS) disorders has been
challenging, due to highly compact blood-brain barrier (BBB) impedes the access of most …

Although the global prevalence of neurological disorders such as Parkinson's disease,
Alzheimer's disease, glioblastoma, epilepsy, and multiple sclerosis is steadily increasing …

Poor brain penetration of tarenflurbil (TFB) was one of the major reasons for its failure in
phase III clinical trials conducted on Alzheimer's patients. Thus there is a tremendous need …